We scan new podcasts and send you the top 5 insights daily.
Shana Kelley says inflammation is dynamic and must be studied in intact tissue with spatial context, not from single petri-dish cells or snapshots. Biohub Chicago is building implantable sensors that track five to ten inflammatory markers and live-tissue omic platforms to capture the molecular landscape.
To study complex processes like inflammation, CZI is developing technologies that go beyond analyzing existing data. This includes implantable sensors that track inflammatory markers in real-time (like a glucose monitor) and "live tissue omic platforms" that can map entire proteomes, creating rich, dynamic datasets to train advanced AI models.
Alex Rives says continuous molecular monitoring would be immensely valuable and likely converge with cell models eventually. Measuring more molecular parameters continuously could directly link bottom-up personal health data with top-down biological understanding of disease, though Biohub itself stays at the enabling technology layer.
CZI's New York Biohub is treating the immune system as a programmable platform. They are engineering cells to navigate the body, detect disease markers like heart plaques, record this information in their DNA, and then be read externally, creating a living diagnostic tool.
By continuously measuring a drug's effect on the body (pharmacodynamics), the wearable device provides a real-time view of a patient's phenotype. This granular data can revolutionize clinical trial design, safety monitoring, and drug dosing, moving beyond static genomic data to understand real-world drug response.
Historically, molecular biology, cell biology, and tissue biology were studied as separate disciplines. Spatial biology technologies like 10x Genomics' Atera platform now allow researchers to measure all three simultaneously and in context, creating a more holistic, unified view of biological systems.
The next frontier in preclinical research involves feeding multi-omics and spatial data from complex 3D cell models into AI algorithms. This synergy will enable a crucial shift from merely observing biological phenomena to accurately predicting therapeutic outcomes and patient responses.
To truly understand biological systems, data scale is less important than data quality. The most informative data comes from capturing the dynamic interactions of a system *while* it's being perturbed (e.g., by a drug), not from static snapshots of a system at rest.
Alex Rives says a complete cell model must include cells in tissue and living systems, not just isolated cultures. Biohub builds real imaging across atomic, cell-culture, and whole-organism scales, including zebrafish microscopes that track every cell and immune-cell trafficking as an embryo develops over time.
Genomic data (DNA) provides a static blueprint of potential, not a view of the actual biological activity. True understanding requires measuring the dynamic interactions of molecules and cells within tissues "downstream." Current methods capture only fragmentary slices, missing the full picture.
Circulating biomarkers like hsCRP show general pathway engagement but cannot identify the specific node of inhibition or reflect local tissue inflammation status. Patients routinely exhibit normal systemic hsCRP despite suffering severe inflammation within the cardiac wall, brain, or liver on imaging. As development in sterile neuroinflammation and cardiology advances, drug developers must increasingly rely on imaging rather than blood tests for indication selection and pharmacodynamic proof.